EGFR-IN-207
EGFR-IN-207 (Compound 5h) is an epidermal growth factor receptor (EGFR) kinase inhibitor with an IC50 of 0.21 μM. EGFR-IN-207 induces cell cycle arrest at the Sub-G1 phase and promotes Apoptosis. EGFR-IN-207 exhibits anticancer activity against lung cancer. EGFR-IN-207 shows extremely low toxicity in non-cancerous cell lines. EGFR-IN-207 can be used in lung cancer-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C20H13Cl2FN6
- Masse moléculaire:427.26
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform EGFR
More
Activité biologique
EGFR-IN-207 potently inhibits the kinase activity of wild-type EGFR with an IC50 of 0.21 ± 0.06 μM, and exhibits better efficacy than Erlotinib (HY-50896)[1].
EGFR-IN-207 (0.1-100 μM; 72 h) results in cell viabilities of 82% and 83% in HBEC30KT and HEK293 cells, respectively, at the concentration of 10 μM[1].
EGFR-IN-207 (0.5-10 μM; 72 h) potently and concentration-dependently inhibits the proliferation of H1975 and A549 human lung cancer cells[1].
EGFR-IN-207 (5 μM; 24 h) induces robust Sub-G1 cell cycle arrest and apoptosis in human lung cancer cell lines H1975 and A549[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:H1975 EGFR L858R/T790M mutant cells, A549 EGFR wild-type cells
-
Concentration:0.5-10 μM
-
Incubation Time:72 h
-
Result:Reduced viable cell percentage to 86% at 1 μM, 34% at 5 μM, and 27% at 10 μM in H1975 cells, surpassing erlotinib's effect (37% viability at 10 μM).
Reduced viable cell percentage to 91% at 1 μM and 36% at 10 μM in A549 cells, with activity comparable to erlotinib.
-
Cell Line:H1975, A549 human lung cancer cells
-
Concentration:5 μM
-
Incubation Time:24 h
-
Result:Increased the apoptotic cell population to 18.7 ± 1.9% (from 1.9 ± 0.4% in control) in H1975 cells, exceeding erlotinib's effect (13.7 ± 3.2%).
Increased the apoptotic cell population to 15.8 ± 2.1% (from 2.1 ± 0.2% in control) in A549 cells, with activity comparable to erlotinib.
Chemical Information
-
Masse moléculaire 427.26
-
Formule C20H13Cl2FN6
-
SMILES
CC1=NN(C2=CC=C(F)C=C2)C3=C1C4=C(N=NN4C5=CC(Cl)=CC(Cl)=C5)C(C)=N3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
EGFR-IN-207 Related Classifications
HY-182073 Related Classifications
Powered by Bioz